These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 33622158)
1. Teprotumumab and hearing loss: hear the warnings. Chern A; Gudis DA; Dagi Glass LR Orbit; 2021 Aug; 40(4):355-356. PubMed ID: 33622158 [No Abstract] [Full Text] [Related]
2. Teprotumumab and Hearing Loss: Case Series and Proposal for Audiologic Monitoring. Belinsky I; Creighton FX; Mahoney N; Petris CK; Callahan AB; Campbell AA; Kazim M; Lee HBH; Yoon MK; Dagi Glass LR Ophthalmic Plast Reconstr Surg; 2022 Jan-Feb 01; 38(1):73-78. PubMed ID: 34085994 [TBL] [Abstract][Full Text] [Related]
3. Thyroid Eye Disease, Teprotumumab, and Hearing Loss: An Evolving Role for Otolaryngologists. Chern A; Dagi Glass LR; Gudis DA Otolaryngol Head Neck Surg; 2021 Dec; 165(6):757-758. PubMed ID: 33781112 [TBL] [Abstract][Full Text] [Related]
4. Rifle Blast Exacerbating Hearing Loss in a Patient Treated With Teprotumumab for Thyroid Eye Disease. Reed DS; Kostosky N; Davies BW; Epstein A; Durairaj VD Ophthalmic Plast Reconstr Surg; 2022 Mar-Apr 01; 38(2):e41-e43. PubMed ID: 34652314 [TBL] [Abstract][Full Text] [Related]
5. Teprotumumab-associated chronic hearing loss screening and proposed treatments. Chow A; Silkiss RZ BMJ Case Rep; 2022 Apr; 15(4):. PubMed ID: 35418378 [TBL] [Abstract][Full Text] [Related]
6. Teprotumumab for the treatment of thyroid eye disease. Ju Y; Yang J Expert Rev Clin Immunol; 2020 Aug; 16(8):739-743. PubMed ID: 32707005 [TBL] [Abstract][Full Text] [Related]
7. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501 [TBL] [Abstract][Full Text] [Related]
8. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies. Winn BJ; Kersten RC Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408 [TBL] [Abstract][Full Text] [Related]